Therapeutic Exposure and Successful Response to Pembrolizumab in a Patient With Non–Small-Cell Lung Cancer Despite Significant Renal Loss Due to Paraneoplastic Nephrotic Syndrome-Reference-Cited by-同舟云学术

Therapeutic Exposure and Successful Response to Pembrolizumab in a Patient With Non–Small-Cell Lung Cancer Despite Significant Renal Loss Due to Paraneoplastic Nephrotic Syndrome

Published:2021-03 Issue:2 Volume:22 Page:e220-e223
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Jansen A.M.E.,Sriram J.D.,Pluim D.,Maas R.J.H.,van Groningen H.,Piet B.,ter Heine R.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference17 articles.

1. Metastatic non–small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

2. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study;Garon;J Clin Oncol,2019

3. Onco-nephrology: glomerular diseases with cancer;Cambier;Clin J Am Soc Nephrol,2012

4. Nephrotic syndrome: components, connections, and angiopoietin-like 4–related therapeutics;Macé;J Am Soc Nephrol,2014

5. Pharmacokinetics of monoclonal antibodies;Ryman;CPT Pharmacometrics Syst Pharmacol,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel factors potentially initiating acute antibody‐mediated rejection in pig kidney xenografts despite an efficient immunosuppressive regimen;Xenotransplantation;2024-03

2. Proteinuria and Exposure to Eculizumab in Atypical Hemolytic Uremic Syndrome;Clinical Journal of the American Society of Nephrology;2023-04-10

3. Pembrolizumab;Reactions Weekly;2021-04